Sirtuins是NAD⁺依賴性的進(jìn)化保守的脫乙酰酶家族，家族內(nèi)不同蛋白在亞細(xì)胞定位和功能方面顯示出多樣性。Sirtuin 2（SIRT2）在全身組織器官中均有表達(dá)，富集于代謝相關(guān)組織，亞細(xì)胞定位顯示其主要存在于細(xì)胞質(zhì)中，并能穿梭于細(xì)胞核內(nèi)，參與多種生理活動，尤其在調(diào)節(jié)代謝方面具有重要作用，是臨床治療代謝性疾病的潛在靶點(diǎn)。目前以SIRT2為靶點(diǎn)的特效藥還處于抑制劑或激動劑研發(fā)階段，尚未有相關(guān)靶向特效藥物進(jìn)入臨床試驗(yàn)。總結(jié)近年來SIRT2對體內(nèi)外代謝過程的調(diào)控作用、作用靶點(diǎn)和相關(guān)調(diào)節(jié)劑及其與代謝相關(guān)疾病的研究進(jìn)展。

Sirtuins are NAD⁺-dependent evolutionarily conserved families of deacetylases,and different proteins within the family show diversity in subcellular localization and function.Sirtuin 2(SIRT2) is expressed in whole body tissues and organs,and is enriched in metabolic related tissues.Subcellular localization shows that SIRT2 mainly exists in the cytoplasm and can shuttle into the nucleus and participate in various physiological activities,especially in regulating metabolism.An important role of SIRT2 is the potential target for clinical treatment of metabolic diseases.At present,the specific drug targeting SIRT2 is still in the development stage of inhibitors or agonists,and no related specific effects drugs have entered the clinical trial.This review summarizes the recent advances in the regulation of SIRT2 on metabolic processes in vitro and in vivo,targets and related inhibitors or agonists,and their progress in metabolic-related diseases.

國家自然科學(xué)基金面上項(xiàng)目（81673679）